LabCorp Extends Offer for Orchid for Sixth Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said it has extended its cash tender offer to purchase Orchid Cellmark to 5 p.m. EDT Oct. 7.

The extension is the sixth by LabCorp since it launched its bid for Orchid in April for $2.80 per share, or a total price tag of $85.4 million. The offer had been previously extended to Sept. 9.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.